Novo Holdings buys CDMO Catalent in US$16.5 billion deal
Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk.
The Danish pharmaceutical giant, in headline news regarding its popular semaglutide drug product Wegovy for weight loss indications, will complete the transaction towards the end of this year. The move is expected to enable Novo Nordisk to meet record-high demand for Wegovy with expanded fill-finish capacity.
Novo Holdings acts as the investment arm of the Novo Nordisk Foundation, buying Catalent’s shares for US$11.5 billion. Once the deal is complete, the company plans to sell three fill-finish sites in Italy, Belgium and the US to Novo Nordisk for US$11 billion.
CEO of Novo Holdings Kasim Kutay described the deal in a statement: “We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture, and supply products that help people live better and healthier lives.” The three fill-finish sites employ a total of over 3000 individuals and all have continuing collaborations with their soon-to-be parent company.
Lars Fruergaard Jørgensen stated the acquisition would “enable us to serve significantly more people living with diabetes and obesity in the future... [complementing] the significant investments we are already doing in active pharmaceutical ingredients facilities.” Increasing competition from other pharmaceutical companies in the obesity drug race may cause the market to be worth up to US$100 billion by the end of the decade. US rival Eli Lilly is already FDA approved for chronic weight management.
Sources: Novo Nordisk’s parent to buy Catalent for $16.5 bln to boost Wegovy supply [Accessed February 7, 2024] https://www.reuters.com/markets/deals/novo-holdings-buy-catalent-115-billion-expand-wegovy-capacity-2024-02-05/
Novo Holdings to buy CDMO Catalent for $16.5bn [Accessed February 5, 2024] https://bioprocessintl.com/bioprocess-insider/facilities-capacity/novo-holdings-to-buy-cdmo-catalent-for-16-5bn/
Related News
-
News Special Edition Women in Pharma: International Day of Women and Girls in Science
In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. -
News Pharmapack Awards 2024 Start-up Innovation Award Winner – Capa Valve Ltd
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance